An observational study in Gastric Cancer, Colorectal Cancer and Lung Cancer (NSCLC), sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Samsung Medical Center · Observational
This observational study aims to develop an integrated genomic and clinical database to support the discovery and validation of biomarkers for cancer diagnosis, treatment selection, and prediction of treatment response.
The study will include adults aged 19 years or older with diagnosed or suspected cancer, as well as consenting individuals undergoing routine health screenings at Samsung Medical Center. Researchers will collect residual tissue specimens obtained during routine diagnostic or therapeutic procedures and additional blood samples collected alongside routine clinical blood tests. Previously collected specimens from approved biobank resources may also be used.
Genetic, molecular, and protein analyses will be performed on the collected specimens, and the results will be integrated with clinical information, including cancer diagnosis, treatment history, treatment response, and disease outcomes. Patient-derived organoids and immune cells may also be used to investigate drug responses in laboratory models.
The study aims to identify biomarkers associated with cancer development, progression, and treatment response, and to support the development of diagnostic tools and personalized treatment strategies.
No experimental treatments will be assigned as part of this study, and no additional tissue biopsies will be performed solely for research purposes.
This is an investigator-initiated, observational study conducted at Samsung Medical Center to establish and utilize a comprehensive database integrating genomic, molecular, and clinical information. The primary objective is to discover and validate biomarkers associated with cancer diagnosis, disease progression, treatment response, and therapeutic outcomes.
The study aims to support precision oncology by identifying molecular characteristics associated with different clinical outcomes and developing predictive models for cancer diagnosis and treatment selection.
3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.
This study's planned enrollment of 118,750 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population includes adults aged 19 years or older receiving care or undergoing routine health screening at Samsung Medical Center. Eligible participants include patients with diagnosed or suspected cancer undergoing clinically indicated tissue collection, healthy individuals undergoing routine health screening, and individuals at high risk of gastric or pancreatic cancer. Previously collected tissue and blood specimens from the Samsung Medical Center Biobank and approved research studies may also be included in accordance with applicable consent and ethical requirements. Clinical information and biospecimens will be collected and analyzed to establish an integrated genomic and clinical database for cancer biomarker discovery and treatment response prediction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hematology-Oncology
Gastroenterology
Surgery
Radiation Oncology
Number of Participants with Integrated Genomic and Clinical Data
The number of participants with successfully generated genomic or molecular data linked to clinical information in an integrated database will be assessed. Genomic and molecular data will be obtained from tumor tissue and blood specimens, and linked to clinical information including cancer diagnosis, disease stage, treatment history, treatment response, and clinical outcomes. The integrated database will be used to support biomarker discovery and the development of predictive models for cancer diagnosis and treatment response.
Time frame: From study enrollment through December 31, 2030
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.